Approximately 5.8 million veterans are treated through the U.S. Veterans Affairs system annually, with a substantial portion carrying PTSD diagnoses. Since 2001, the FDA has approved no new medication for this condition, and no neuromodulation device had ever received PTSD clearance. That changed on May 26, 2026, when the FDA approved Modius Spero, a wearable worn behind the ears for 30 minutes daily that clinically reduced PTSD symptoms in two-thirds of 383 trial participants.
What Modius Spero is and how it works
The device, made by Northern Irish company Neurovalens, stimulates the vagus nerve transcutaneously behind the ears: small electrical impulses through the skin, without surgery or implantation. The vagus nerve connects body and brain directly. It regulates, among other functions, the amygdala, the brain region that in PTSD becomes hyperactive in response to stress triggers and triggers fear and avoidance reactions. Transcutaneous vagus nerve stimulation (tVNS) is the principle behind the device: a non-invasive variant of a procedure already used in implanted form for epilepsy and severe depression.
The application is deliberately designed to be low-barrier: 30 minutes daily, at home, without a clinic visit for each use. Patients can watch television, read, or sit quietly while using it. The device aims to enable a daily therapeutic dose that integrates into daily life rather than requiring a separate treatment location.
Why nothing new emerged for 25 years
The PTSD treatment landscape has barely changed structurally since the last medication approval for PTSD in 2001. Today, first-line treatments are SSRI antidepressants such as sertraline and paroxetine, as well as trauma-focused psychotherapies like Cognitive Processing Therapy (CPT) and EMDR. These approaches are clinically well-established and help many people. But not everyone: a substantial portion of patients does not respond adequately to first and second-line treatments. Adding to the challenge are structural barriers: therapy slots are scarce in rural U.S. areas, and people with severe PTSD often actively avoid clinical settings because external triggers can themselves be activating.
The treatment gap is particularly well-documented for veterans. According to a 2025 study published in the Journal of Clinical Psychiatry (National Health and Resilience in Veterans Study), 14.4 percent of all U.S. veterans develop PTSD in their lifetime. Among veterans who served in Afghanistan or Iraq, the rate is approximately 29 percent. Of the 5.8 million veterans treated through the VA system in fiscal year 2024, 14 percent of men and 24 percent of women received a PTSD diagnosis.
What the approval trial shows
The FDA based its De Novo approval on a U.S. study of 383 adults with clinically confirmed PTSD diagnoses. Neurovalens reported that two-thirds of participants showed clinically meaningful improvement in their symptoms. The De Novo category is not a streamlined process; it applies to novel devices without a directly comparable product on the market and requires complete safety and efficacy evidence.
One caveat: at the time of approval, detailed study data had not yet been published in a fully peer-reviewed journal. The FDA decision rests on submitted documentation. For independent scientific assessment, published results are necessary.
Compared to existing PTSD treatments
Sertraline, the most commonly prescribed PTSD medication, shows response rates around 53 percent in randomized controlled trials; paroxetine around 62 percent. Vagus nerve stimulation combined with cognitive behavioral therapy (VNS+CBT) achieved a 85 percent response rate in a 2025 study from the University of Texas at Dallas, but requires a surgically implanted stimulator. MDMA-assisted psychotherapy showed consistently stronger effects than placebo in Phase III trials but remains unapproved in any country.
Modius Spero occupies a specific niche: non-invasive, without implantation, without requiring clinic visits for each application. This is not a minor advantage for a condition where avoidance behavior is a central symptom and treatment dropout often results from external barriers.
Three conditions for the device to have broad impact
Neurovalens plans to make Modius Spero available to U.S. veterans starting July 2026 through the VA. This is the most direct path to the most severely affected populations. Whether the approval leads to broad access depends on three conditions.
First, the VA must actually implement reimbursement. VA approvals for new medical devices have historically been delayed by budget processes and internal prioritization. Summer 2026 availability is the plan, not yet a guarantee.
Second, coverage by private U.S. health insurance must be clarified. Without reimbursement, the device remains unaffordable for people with inadequate insurance. This disproportionately affects those most at risk for PTSD.
Third, European approval is completely absent. For millions of people in Germany, Austria, and Switzerland who develop PTSD during their lives, Modius Spero remains inaccessible for now. Neurovalens has, according to its statements, initiated discussions with European authorities, but no public timeline exists.